August 1969

Attenuated Rubella Virus Vaccines in Children With TuberculosisClinical Trials

Author Affiliations

From the Laboratory of the Société d'Etudes et de Soins pour les Enfants Poliomyelitiques, Château de Longchamp, Paris.

Am J Dis Child. 1969;118(2):258-260. doi:10.1001/archpedi.1969.02100040260019

IN ORDER TO demonstrate the lack of communicability of attenuated rubella virus strains, clinical trials have been performed in institutions housing closed populations of children. We report here the results of clinical trials of live rubella virus vaccines undertaken in an institution for young children with pulmonary tuberculosis. This institution was selected for study because the conditions of isolation and of medical surveillance were very good.

Materials and Methods  Vaccines.—Two attenuated rubella virus vaccines were used: (1) HPV-77 vaccine prepared in green monkey kidney tissue cultures, and (2) RA 27/3 vaccine prepared in WI 38 human diploid cell lines. Each vaccinated child received 0.5 ml subcutaneously.Study Population and Experimental Design.—This study was done in the isolation unit of the "Centre de Protection Infantile" of Bullion, an institution for treatment of children less than 5 years of age with pulmonary tuberculosis. This institution is located in the

First Page Preview View Large
First page PDF preview
First page PDF preview